Clinical pearls: Laboratory assessments of direct oral anticoagulants (DOACS)

Robert Gosselin, Robert Gosselin, Jonathan Douxfils, Dorothy Adcock

Résultats de recherche: Recherche - Revue par des pairsArticle de revue

Résumé

Direct oral anticoagulants (DOACS) are being used for stroke prevention in patients with atrial fibrillation as well as for prophylaxis and treatment of venous thromboembolism. Clinicians who treat, or may encounter, patients with DOAC exposure, should be aware of the limitations of coagulation testing in this setting, and seek counsel from their laboratory to understand the effects of DOACS on coagulation results. Generally, assays that employ clot based principles, or methods that require thrombin or Factor Xa activation or substrates may be affected by the presence of DOACS. The clinical laboratory should have an algorithmic testing plan for adequately assessing the presence of all DOACS and readily provide this information to clinicians. We describe Clinical Pearls for DOAC assessment using common and esoteric coagulation testing.

langueAnglais
journalHamostaseologie
Volume37
Numéro4
Les DOIs
étatE-pub ahead of print - 2017

Empreinte digitale

Anticoagulants
Factor Xa
Venous Thromboembolism
Thrombin
Atrial Fibrillation
Stroke
Therapeutics

mots-clés

    Citer ceci

    Gosselin, Robert ; Gosselin, Robert ; Douxfils, Jonathan ; Adcock, Dorothy. / Clinical pearls : Laboratory assessments of direct oral anticoagulants (DOACS). Dans: Hamostaseologie. 2017 ; Vol 37, Numéro 4.
    @article{ca57537f022a4e7799d05c4e0c172c65,
    title = "Clinical pearls: Laboratory assessments of direct oral anticoagulants (DOACS)",
    abstract = "Direct oral anticoagulants (DOACS) are being used for stroke prevention in patients with atrial fibrillation as well as for prophylaxis and treatment of venous thromboembolism. Clinicians who treat, or may encounter, patients with DOAC exposure, should be aware of the limitations of coagulation testing in this setting, and seek counsel from their laboratory to understand the effects of DOACS on coagulation results. Generally, assays that employ clot based principles, or methods that require thrombin or Factor Xa activation or substrates may be affected by the presence of DOACS. The clinical laboratory should have an algorithmic testing plan for adequately assessing the presence of all DOACS and readily provide this information to clinicians. We describe Clinical Pearls for DOAC assessment using common and esoteric coagulation testing.",
    keywords = "Journal Article",
    author = "Robert Gosselin and Robert Gosselin and Jonathan Douxfils and Dorothy Adcock",
    year = "2017",
    doi = "10.5482/HAMO-17-01-0002",
    volume = "37",
    journal = "Hamostaseologie",
    issn = "0720-9355",
    publisher = "Schattauer GmbH",
    number = "4",

    }

    Clinical pearls : Laboratory assessments of direct oral anticoagulants (DOACS). / Gosselin, Robert; Gosselin, Robert; Douxfils, Jonathan; Adcock, Dorothy.

    Dans: Hamostaseologie, Vol 37, Numéro 4, 2017.

    Résultats de recherche: Recherche - Revue par des pairsArticle de revue

    TY - JOUR

    T1 - Clinical pearls

    T2 - Hamostaseologie

    AU - Gosselin,Robert

    AU - Gosselin,Robert

    AU - Douxfils,Jonathan

    AU - Adcock,Dorothy

    PY - 2017

    Y1 - 2017

    N2 - Direct oral anticoagulants (DOACS) are being used for stroke prevention in patients with atrial fibrillation as well as for prophylaxis and treatment of venous thromboembolism. Clinicians who treat, or may encounter, patients with DOAC exposure, should be aware of the limitations of coagulation testing in this setting, and seek counsel from their laboratory to understand the effects of DOACS on coagulation results. Generally, assays that employ clot based principles, or methods that require thrombin or Factor Xa activation or substrates may be affected by the presence of DOACS. The clinical laboratory should have an algorithmic testing plan for adequately assessing the presence of all DOACS and readily provide this information to clinicians. We describe Clinical Pearls for DOAC assessment using common and esoteric coagulation testing.

    AB - Direct oral anticoagulants (DOACS) are being used for stroke prevention in patients with atrial fibrillation as well as for prophylaxis and treatment of venous thromboembolism. Clinicians who treat, or may encounter, patients with DOAC exposure, should be aware of the limitations of coagulation testing in this setting, and seek counsel from their laboratory to understand the effects of DOACS on coagulation results. Generally, assays that employ clot based principles, or methods that require thrombin or Factor Xa activation or substrates may be affected by the presence of DOACS. The clinical laboratory should have an algorithmic testing plan for adequately assessing the presence of all DOACS and readily provide this information to clinicians. We describe Clinical Pearls for DOAC assessment using common and esoteric coagulation testing.

    KW - Journal Article

    U2 - 10.5482/HAMO-17-01-0002

    DO - 10.5482/HAMO-17-01-0002

    M3 - Review article

    VL - 37

    JO - Hamostaseologie

    JF - Hamostaseologie

    SN - 0720-9355

    IS - 4

    ER -